1. Moderate-to-Severe Asthma Management

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. Asthma Introduction

4. The Unmet Medical Needs of Asthma

5. Asthma Is a Heterogeneous Disease

6. Case: Stephanie

7. Achieving Control in Asthma

8. Assessing Asthma Control

9. Assessing Future Risk

10. The Goal of Asthma Management

11. Triggers and Comorbidities

12. Adherence and Persistence to Asthma Medication

13. Shared Decision Making in Asthma Management

14. GINA-Based Steps for Asthma Treatment

15. Case: Stephanie – 10 Months Later

16. Defining "Severe Asthma"

17. Pathobiology of Asthma

18. Pathobiology of Asthma

19. Emerging Asthma Phenotypes

20. Asthma Biomarkers

21. Current and Emerging Targeted Therapies for Severe Asthma

22. Omalizumab: an Anti-IgE Agent

23. Anti-IL-5 Therapy in Eosinophilic Asthma

24. Anti-IL-5 Therapy in Eosinophilic Asthma

25. Investigational Agents for Severe Asthma

26. Take-Home Points

27. Abbreviations

28. Abbreviations (cont)